Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Younis IR"'
Publikováno v:
Clinical Pharmacology & Therapeutics; Oct2017, Vol. 102 Issue 4, p578-580, 3p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Younis IR; Gilead Sciences, Inc., Foster City, CA, USA., Nelson C; Gilead Sciences, Inc., Foster City, CA, USA., Weber EJ; Gilead Sciences, Inc., Foster City, CA, USA., Shen G; Gilead Sciences, Inc., Foster City, CA, USA., Qin AR; Gilead Sciences, Inc., Foster City, CA, USA., Xiao D; Gilead Sciences, Inc., Foster City, CA, USA., Watkins TR; Gilead Sciences, Inc., Foster City, CA, USA., Othman AA; Gilead Sciences, Inc., Foster City, CA, USA.
Publikováno v:
Journal of clinical pharmacology [J Clin Pharmacol] 2024 Aug 30. Date of Electronic Publication: 2024 Aug 30.
Autor:
Ahmed MA; Quantitative Clinical Pharmacology, Takeda Development Center, Cambridge, Massachusetts, USA., Krishna R; Certara Drug Development Solutions, Certara USA, Inc., Princeton, New Jersey, USA., Rayad N; Parexel International (MA) Corporation, Mississauga, Ontario, Canada.; Clinical Pharmacology and Safety Sciences, Alexion, AstraZeneca Rare Disease, Mississauga, ON, Canada., Albusaysi S; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia., Mitra A; Clinical Pharmacology, Kura Oncology Inc, Boston, Massachusetts, USA., Shang E; Global Regulatory Affairs and Clinical Safety, Merck &Co., Inc., Rahway, New Jersey, USA., Hon YY; Divsion of Rare Diseases and Medical Genetics, Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine, US Food and Drug Administration, Silver Spring, Maryland, USA., AbuAsal B; Division of Translational and Precision Medicine, Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, Maryland, USA., Bakhaidar R; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia., Roman YM; Division of Translational and Precision Medicine, Office of Clinical Pharmacology, US Food and Drug Administration, Silver Spring, Maryland, USA., Bhattacharya I; Quantitative Clinical Pharmacology, Takeda Development Center, Cambridge, Massachusetts, USA., Cloyd J; Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Patel M; Quantitative Clinical Pharmacology, Takeda Development Center, Cambridge, Massachusetts, USA., Kartha RV; Center for Orphan Drug Research, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Younis IR; Quantitative Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Aug 16. Date of Electronic Publication: 2024 Aug 16.
Autor:
Mitra A; Clinical Pharmacology, Kura Oncology Inc., Boston, Massachusetts, USA., Tania N; Translational Clinical Sciences, Pfizer Research and Development, Cambridge, Massachusetts, USA., Ahmed MA; Quantitative Clinical Pharmacology, Takeda Development Center, Cambridge, Massachusetts, USA., Rayad N; Clinical Pharmacology, Modeling and Simulation, Parexel International (Canada) LTD, Mississauga, Ontario, Canada., Krishna R; Certara Drug Development Solutions, Certara USA, Inc., Princeton, New Jersey, USA., Albusaysi S; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia., Bakhaidar R; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia., Shang E; Global Regulatory Affairs and Clinical Safety, Merck &Co., Inc., Rahway, New Jersey, USA., Burian M; Clinical Science, UCB Biopharma SRL, Braine-l'Alleud, Belgium., Martin-Pozo M; Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Younis IR; Quantitative Pharmacology and Pharmacometrics, Merck &Co., Inc., Rahway, New Jersey, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 Jul 11. Date of Electronic Publication: 2024 Jul 11.
Autor:
Younis IR; Gilead Sciences Inc, Foster City, California, USA., Nelson C; Gilead Sciences Inc, Foster City, California, USA., Weber EJ; Gilead Sciences Inc, Foster City, California, USA., Qin AR; Gilead Sciences Inc, Foster City, California, USA., Watkins TR; Gilead Sciences Inc, Foster City, California, USA., Othman AA; Gilead Sciences Inc, Foster City, California, USA.
Publikováno v:
Journal of clinical pharmacology [J Clin Pharmacol] 2024 Jul; Vol. 64 (7), pp. 878-886. Date of Electronic Publication: 2024 Mar 22.
Autor:
Younis IR; Gilead Sciences, Inc., Foster City, CA, USA., Wang F; College of Pharmacy, University of Minnesota, Minneapolis, MN, USA., Othman AA; Gilead Sciences, Inc., Foster City, CA, USA.
Publikováno v:
Journal of clinical pharmacology [J Clin Pharmacol] 2024 Jun; Vol. 64 (6), pp. 713-718. Date of Electronic Publication: 2024 Feb 12.
Autor:
Weber EJ; Gilead Sciences, Inc., Foster City, CA, USA., Younis IR; Gilead Sciences, Inc., Foster City, CA, USA., Wang L; Gilead Sciences, Inc., Foster City, CA, USA., Xiao D; Gilead Sciences, Inc., Foster City, CA, USA., Barchuk WT; Gilead Sciences, Inc., Foster City, CA, USA., Othman AA; Gilead Sciences, Inc., Foster City, CA, USA.
Publikováno v:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Jun; Vol. 13 (6), pp. 677-687. Date of Electronic Publication: 2024 Feb 12.
Autor:
Avachat C; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Younis IR; Department of Quantitative Clinical Pharmacology and Pharmacometrics, Merck & Co., Inc., Rahway, New Jersey, USA., Birnbaum AK; Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Dec; Vol. 114 (6), pp. 1238-1242. Date of Electronic Publication: 2023 Oct 13.
Autor:
Mitra A; Clinical Pharmacology, Kura Oncology, Boston, Massachusetts, USA., Ahmed MA; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA., Krishna R; Integrated Drug Development, Certara USA, Inc., Princeton, New Jersey, USA., Sun K; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA., Gibbons FD; Quantitative Solutions, Preclinical and Translational Sciences, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA., Campagne O; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA., Rayad N; Clinical Pharmacology, Modeling and Simulation, Parexel International (MA) Corporation, Mississauga, Ontario, Canada., Roman YM; Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA., Albusaysi S; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia., Burian M; Translational Medicine Neuroscience and Gene Therapy, UCB Biopharma SRL, Braine-l'Alleud, Belgium., Younis IR; Clinical Pharmacology Sciences, Gilead Science, Inc, Foster City, California, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Sep; Vol. 114 (3), pp. 515-529. Date of Electronic Publication: 2023 Jun 29.